山東新華製藥(00719.HK)非公開發行股票申請遭中證監中止審查
山東新華製藥股份(00719.HK)(000756.SZ)公佈,有關公司擬向華魯投資發展非公開發行股票一事,昨日(26日)公司收到中國證監會出具的《中國證監會行政許可申請中止審查通知書》,因中國證監會在審查公司非公開發行股票申請文件的行政許可過程中,公司聘請的非公開發行審計機構信永中和會計師事務所被中國證監會立案調查,中國證監會決定中止對該行政許可申請的審查。
公司指,將在具備恢復審查條件後,向中國證監會提交申請恢復對是次非公開發行A股股票申請文件的審查。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.